



Press release, August 29, 2013

Allenex receive XM-ONE® approval for sale in Mexico

Allenex application to sell AbSorbers product for antibody detection, XM-ONE®, in Mexico has been approved by local regulatory authorities. XM-ONE® is a cross match test developed and manufactured by AbSorber, for detection of HLA- and non-HLA antibodies between the donor and the recipient in organ transplantation. The application has been handled by Allenex local representative Biodist S.A. de C.V., a leading company in the Mexican diagnostic market.

"Mexico is an important country for our geographical expansion and a priority in our growth strategy. We are especially satisfied with the performance of Biodist, having two of our product lines registered in a short time. We see a high probability being able to sell both Olerup SSP® products as well as XM-ONE® in Mexico in the near future", Allenex CEO Anders Karlsson comments.

In Mexico a large proportion of sales occur through contracts within various health insurance schemes, and the right sales channels are therefore important in a product launch. The launch of XM-ONE® will start immediately and the focus in the near term will be to have the product brought onto the list of specialty tests available for HLA laboratories within the country.

"We are very pleased with the approval of XM-ONE®. We expect to launch the test as a specialty test for selected clients within our transplantation network. Already today customers have shown interest to evaluate the test and several of them have already tested it in their own laboratories. In the short period that Biodist has been partners with Allenex we have already registered two product lines in Mexico and we also want to include other Allenex products in the collaboration," says Rebeca Miramontes Vidal, CEO at Biodist.

For more information please contact:

Anders Karlsson, CEO Allenex AB, ph: +4670-918 00 10, e-mail: anders.karlsson@allenex.se

Allenex AB discloses the information provided herein pursuant to the Securities Markets Act and /or the Financial Instruments Trading Act. The information was submitted for publication on August 29, 2013, at 08.40 CET. Allenex is a life science-company that develops, manufacture, market and sell products for safer transplants of organs and bone marrow on the global market. Allenex is listed on NASDAQ OMX Stockholm Small Cap (ticker: ALNX). 54 persons are employed in the Allenex group.